NORTH BRUNSWICK, NJ, Feb. 17 10, 2022 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a private, clinical-stage company developing therapies for inflammatory, infectious and degenerative diseases based on a portfolio built around gelsolin technology, announces the appointment of Dr. Kerry Maguire and Kris Vinckier to the Board of Directors, effective February 15, 2022.
Kerry Maguire, DDS, MSPH, brings extensive clinical and global health expertise
Dr. Kerry Maguire is a healthcare executive who most recently served as Vice President of Clinical Operations at the Forsyth Institute in Cambridge, MA. As a public health professional, she has focused on health disparities of vulnerable populations, primarily children and people living with HIV.
Kerry has held faculty positions at Tufts University School of Dental Medicine and the University of Colorado, where she taught didactic and clinical courses and participated in the governance of schools, universities and colleges.
Dr. Maguire also led the Academic Relations team at Colgate Oral Pharmaceuticals and served as Director of Professional Advocacy at Tom’s of Maine. She currently serves on the boards of the American Academy of Pediatric Dentistry Foundation, The Children’s Trust, and Options for Children in Zambia, an organization she founded with BioAegis co-founder Dr. Tom Stossel to fighting oral health, HIV and sickle cell disease. cell disease in rural Africa.
Kerry graduated with honors from the University of Colorado School of Dentistry and completed an advanced education residency in general dentistry the following year. She received her Master of Science in Public Health from the University of Colorado School of Medicine.
“I am delighted to have the opportunity to contribute to the advancement of this technology. My belief that gelsolin can improve global health is a continuation of Tom’s legacy – and my passion for making a difference,” Dr. Maguire shared.
Kris Vinckier brings over 35 years of financial, strategic and leadership experience
Kris Vinckier is a director and co-founder of Paradox Investment Management BV, which manages the investment fund Paradox Investment Network BV, a private Privak under Belgian law. Mr. Vinckier is a seasoned financial and business services executive, currently serving as Head of Life and Benefits Business Strategy for Vivium, a brand of P&V Group, one of Belgium’s leading insurance companies. .
Mr. Vinckier has over 35 years of experience in C-level leadership positions, including leading the integration of complex and diverse aspects of business operations, from risk analysis and product development to implementation and optimization of organizational effectiveness through marketing, including the development of end solutions. market distribution channels.
Kris Vinckier has negotiated high-level policies with political and regulatory bodies and consulted on acquisition transactions. He has led postgraduate leadership and strategy programs focused on banking and insurance.
“As a new member of the Board of Directors, I will strive to bring my knowledge, experience and perspective to the BioAegis Board of Directors,” said Mr. Vinckier. “Thanks to the additional capital from Paradox, BioAegis is now on the verge of rapidly advance new indications, by developing the BioAegis pipeline. »
Mr. Vinckier obtained his undergraduate degree and his master’s degree in physical education and movement sciences at the Faculty of Medicine of the University of Leuven in Belgium.
About BioAegis
BioAegis Therapeutics Inc. is a clinical-stage private company based in New Jersey whose mission is to leverage a key component of the body’s innate immune system, gelsolin, to prevent the adverse effects of diseases caused by inflammation and infection.
BioAegis’ is based on the recombinant form of plasma gelsolin, an abundant human protein highly conserved in healthy individuals. Its role is to maintain localized inflammation at the site of injury and stimulate the body’s ability to eliminate pathogens., but normal levels are depleted by various inflammatory conditions. Restoring gelsolin levels with the recombinant human form helps immune cells fight infection and control inflammation so it doesn’t spread and cause damage.
BioAegis is the exclusive licensee of extensive worldwide intellectual property through Harvard-Brigham and Women’s Hospital. It holds more than 40 issued patents for coverage of infections, inflammatory diseases, kidney failure, multiple sclerosis and other neurological diseases. BioAegis will also have biologics exclusivity in the United States and has recently filed new intellectual property in areas of unmet need.
Investor requests:
Steven Cordovano
203-952-6373
[email protected]
Media inquiries:
Christine Lagana
[email protected]
This press release contains express or implied forward-looking statements, which are based on management’s current expectations. These statements relate to, among other things, our expectations regarding management’s plans, objectives and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these statements. prospective. BioAegis undertakes no obligation to update any forward-looking statements in this press release as circumstances change or otherwise, and such statements speak only as of the date they are made.
